Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

A non-invasive test of oocyte quality in assisted conception

The University of Western Ontario - Industry Liaison
An innovative, real-time test of oocyte quality, applicable to assisted conception treatments, that does no harm to the oocyte itself.

Full description

DESCRIPTION OF INVENTION: Western researchers have developed an innovative, real-time test of oocyte quality, applicable to assisted conception treatments, that does no harm to the oocyte itself. The present invention comprises a methodology to test strength of gap junctional coupling among follicular cells as a surrogate measurement of oocyte health. The invention is based on findings by Western researchers, that gap junctional coupling among follicle cells is a determinant of oocyte quality in humans. Since the follicle cells can easily be detached from the oocyte and are routinely discarded during the assisted conception treatment, their analysis for coupling strength does not compromise the oocyte or the embryo that develops from it. We see the approach as a straightforward method that can be applied on a “real-time” basis, by the IVF laboratory staff to compare and pick the best quality oocytes to enhance the likelihood of success of assisted conception. By providing more certainty, there will be less need to transfer several fertilized oocytes, which is current practice and in many cases results in multiple pregnancies and has significant associated risk to the mother and her unborn babies.

BACKGROUND: Assisted conception treatments have become essential for combating the rising tide of infertility in developed countries, and have since 1978 allowed thousands of infertile couples to have children. However the success rate for assisted conception procedures is still only approximately 20-30%. The practice of transferring multiple embryos to a woman’s uterus is an approach to increasing the probability of success for the procedure. While this practice indeed results in better success rates, it is also associated with the significant risk of multiple pregnancies, which, in turn, are associated with complications that can include fetal growth restriction and premature birth. A reliable, safe and real-time methodology to determine oocyte health will help in predicting which oocytes are most likely to succeed and as a result, significantly reduce the number of embryos that need to be transferred.

POTENTIAL ADVANTAGES/USES:

  • Real time, non-invasive methodology to reliably predict oocyte health
  • No ethical issues with utilizing follicular cells for testing
  • Reduces the need to transfer multiple embryos
  • Reduces safety risks associated with multiple pregnancies
  • Reduces healthcare costs associated with in vitro fertilization

Patent information

US Provisional Application filed

Licensing contact

Dr. Susanne Acklin
Industry Liaison Officer
Industry Liaison, Research Western
Request more information

Company details

The University of Western Ontario - Industry Liaison
Industry Liaison is the technology transfer office of The University of Western Ontario

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Partnering consultation free of charge
Maximizing Pharmaceutical Patent Lifecycles
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us